Immunotherapy for Melanoma

Introduction

This article explains how immunotherapy is used in the treatment of melanoma, a type of skin cancer. It covers how these treatments work, which types are commonly used, who may be eligible, and what practical considerations exist, including risks, availability, and cost. The information is intended to support research and informed discussions with healthcare professionals.

What Is Immunotherapy for Melanoma?

Immunotherapy is a form of cancer treatment that works by activating or enhancing the body’s immune response against cancer cells. Melanoma is considered one of the most immunogenic cancers, meaning it is more easily recognised by the immune system than many other tumour types. This is partly due to the large number of genetic mutations caused by ultraviolet (UV) exposure.

Melanoma cells can still avoid immune attack by sending signals that tell immune cells to stop responding. Immunotherapy drugs block these signals, allowing immune cells—especially T cells—to recognise and destroy melanoma cells more effectively. Rather than targeting the tumour directly, these treatments modify how the immune system behaves.

Immunotherapy has become a standard treatment for advanced melanoma and is also used after surgery in high-risk cases to reduce the chance of recurrence. It has fundamentally changed outcomes for many people with metastatic melanoma.

Common Types of Immunotherapy Used

Melanoma has one of the widest ranges of approved immunotherapy options, and combinations are often used to improve effectiveness.

Immune checkpoint inhibitors

These are the most widely used treatments for melanoma and include:

• PD-1 inhibitors (such as pembrolizumab and nivolumab), often used as first-line therapy

• CTLA-4 inhibitors (such as ipilimumab), sometimes combined with PD-1 inhibitors for a stronger immune response

• LAG-3 inhibitors, a newer class used in combination with PD-1 inhibitors in some settings

These drugs work by removing immune “brakes” that prevent T cells from attacking cancer cells.

Oncolytic virus therapy

This involves injecting a modified virus directly into melanoma tumours. The virus kills cancer cells and triggers an immune response that can also affect tumours elsewhere in the body.

Cytokine therapy

Older immune treatments such as interleukin-2 (IL-2) stimulate immune activity but are used less frequently today due to side effects and the availability of newer options.

Adoptive cell therapy

This includes treatments such as tumour-infiltrating lymphocyte (TIL) therapy, where immune cells are collected from a tumour, expanded in a laboratory, and then reinfused into the patient. These therapies are usually offered in specialised centres or clinical trials.

Cancer vaccines (experimental)

Vaccines designed to train the immune system to recognise melanoma-specific antigens are still being studied and are not yet part of routine care.

Who May Be Eligible?

Eligibility for melanoma immunotherapy depends on disease stage, tumour features, and general health. A medical oncologist determines suitability using clinical assessment and laboratory testing.

People who may be eligible include:

• Stage III or IV melanoma, particularly when the cancer cannot be fully removed by surgery

• High-risk melanoma after surgery, where immunotherapy is used to reduce recurrence

• Unresectable or metastatic disease, where the cancer has spread to distant organs

• Patients with BRAF mutations, who may be candidates for both targeted therapy and immunotherapy

• Patients with good overall health, who can tolerate potential immune-related side effects

People with active autoimmune disease or severe organ dysfunction may not be suitable candidates, as immunotherapy can worsen immune-related conditions.

Benefits and Limitations

Benefits

• High response rates compared to many other cancers

• Long-term remission in some patients, even with advanced disease

• Improved survival for metastatic melanoma compared to older treatments

• Potential to reduce recurrence when used after surgery

• Different side effect profile than chemotherapy

Limitations

• Not all patients respond, with response rates typically ranging from 20–40%

• Resistance can develop, either early or after an initial response

• Combination therapy increases side effects, although it may improve outcomes

• Delayed response, as immune activation takes time

• Close monitoring required, particularly early in treatment

Side Effects and Risks

Immunotherapy side effects occur when the immune system attacks healthy tissues. Most are manageable if detected early, but some can be serious.

Common side effects

• Fatigue

• Skin rash or itching

• Diarrhea

• Joint or muscle pain

• Flu-like symptoms

Less common but serious side effects

• Colitis (bowel inflammation)

• Pneumonitis (lung inflammation)

• Hepatitis (liver inflammation)

• Endocrine disorders, including thyroid or pituitary inflammation

• Skin pigment changes, such as vitiligo

Combination therapies have a higher risk of immune-related side effects, which may require steroids or hospital treatment.

Availability

Immunotherapy for melanoma is widely available in many countries and is considered standard treatment in most modern oncology centres.

• Public hospitals often provide approved immunotherapies through national healthcare systems

• Private clinics may offer faster access or additional options

• Cancer centres and academic hospitals frequently provide combination therapies and clinical trials

• Specialised skin cancer clinics may offer treatments such as oncolytic virus therapy or TIL therapy

• Global availability varies, but access is generally strong in North America, Europe, and parts of Asia

Cost Overview

The cost of melanoma immunotherapy varies by country, regimen, and treatment duration.

• Single-agent therapy may cost $10,000–$15,000 USD per month

• Combination therapy (using two drugs) can cost $20,000–$30,000 USD per month

• Total treatment costs over one to two years can exceed $150,000–$200,000 USD

In countries with public healthcare systems, these costs are often subsidised for eligible patients. Insurance coverage and clinical trials may also reduce out-of-pocket expenses.

How People Typically Find Clinics

Most people access melanoma immunotherapy through standard medical pathways.

Common routes include:

• Dermatologist referrals after a melanoma diagnosis

• Surgical oncology follow-up, especially after tumour removal

• Medical oncology clinics within hospitals or cancer centres

• Specialised melanoma clinics offering advanced or trial therapies

• Independent directories that allow users to browse immunotherapy clinics globally without promotional intent

Patients should always confirm treatment availability and eligibility directly with providers.

Closing Note

Immunotherapy has transformed melanoma from one of the most difficult cancers to treat into one with meaningful long-term survival for many patients. However, it is not suitable for everyone and requires careful specialist oversight. This article is intended to provide balanced, educational information to support further research and informed discussions with qualified healthcare professionals.

Disclaimer: This article is for informational purposes only and does not provide medical advice. Immunotherapy treatments, eligibility, and availability vary by country and individual circumstances. Always consult a qualified healthcare professional and verify information directly with medical providers.